65,437 trials
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression Free Survival (PFS) — 3.5; 3.0 months — p=0.49
Glaucoma
Primary: Primary Endpoints — 97.2; 83.9; 73.9; 336.1 microns
Carcinoma, Adenoid Cystic · Head and Neck Neoplasms
Primary: Tumor Progression — 0; 0; 7; 4 Participants
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Breast Cancer
Primary: Lesions — 0; 12 lesions
Hypertension
Primary: 24 Hour Blood Pressure Average at the End of 4 Month Participation. — 134; 132 mm Hg
Actinic Keratosis
Primary: Overall Patient Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT) — 90.9; 21.9 percentage of participants
Lymph Node Resection
Primary: Percentage of Participants With Post-Operative Seroma Formation Over Time as Determined at Hospital Discharge — 2.63 percentage of participants
Tourettes Syndrome · Tic
Primary: Improvement in Tic Severity — 24.3; 21.3 units on a scale
Continuation Rate of Contraceptive Implant
Primary: Continuation Rate — 20; 18 participants
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Secondary Hyperparathyroidism
Primary: Number of Participants With Adverse Events — 3; 0; 0; 0 participants
Hypertension
Primary: Change From Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP) — -8.776; -22.093; -23.731 mmHg — p=<0.001
Post Menopausal Osteoporosis
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months — 1.87; 2.33; 2.95; 5.80 Percent change — p=0.0066
Major Depressive Disorder · Dysthymic Disorder
Primary: Change From Baseline in Beck Depression Inventory-Second Edition (BDI-II) at the End of Therapy, 3 and 12-month Follow-up — 37.23; 36.94; -17.62; -15.52 units on a scale…
Anxiety · Pain
Primary: Anxiety Measured by VAS — 4; 3 cm — p=0.08